CJD (Creutzfeldt-Jakob Disease) Quinacrine Study

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Creutzfeldt-Jakob Disease
Interventions
DRUG

Quinacrine

100mg by mouth three times a day

DRUG

Placebo

100mg by mouth three times a day

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of California, San Francisco

OTHER

NCT00183092 - CJD (Creutzfeldt-Jakob Disease) Quinacrine Study | Biotech Hunter | Biotech Hunter